FGFR3 (G697C)
Sign in to save this workspaceFGFR3 · Variant type: point · HGVS: p.G697C
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Infigratinib | 99.3% | 0.8% | 98.24 |
| 2 | Erdafitinib | 99.0% | 0.9% | 95.71 |
| 3 | Futibatinib | 99.0% | 1.0% | 98.48 |
| 4 | Pemigatinib | 98.5% | 1.5% | 98.23 |
| 5 | Alpelisib | 97.8% | 2.2% | 97.22 |
| 6 | Ponatinib | 97.4% | 2.6% | 78.23 |
| 7 | Deucravacitinib | 94.5% | 5.5% | 98.99 |
| 8 | Tenalisib | 93.8% | 6.2% | 97.98 |
| 9 | Pralsetinib | 93.5% | 6.5% | 93.43 |
| 10 | Axitinib | 93.0% | 7.0% | 93.23 |
| 11 | Brigatinib | 90.3% | 9.8% | 82.96 |
| 12 | Nintedanib | 89.5% | 10.4% | 90.23 |
| 13 | Lenvatinib | 87.1% | 12.9% | 97.74 |
| 14 | Selpercatinib | 81.7% | 18.3% | 96.72 |
| 15 | Pazopanib | 80.8% | 19.2% | 97.49 |
| 16 | Pacritinib | 73.8% | 26.2% | 88.64 |
| 17 | Entrectinib | 72.7% | 27.3% | 93.69 |
| 18 | Ibrutinib | 72.0% | 28.0% | 94.74 |
| 19 | Tepotinib | 69.1% | 30.9% | 99.75 |
| 20 | Sunitinib | 68.5% | 31.4% | 91.73 |
| 21 | Defactinib | 67.8% | 32.2% | 92.68 |
| 22 | Fedratinib | 63.9% | 36.1% | 96.21 |
| 23 | Ripretinib | 60.9% | 39.1% | 92.95 |
| 24 | Repotrectinib | 51.9% | 48.1% | 84.21 |
| 25 | Tivozanib | 45.6% | 54.4% | 92.42 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Infigratinib | 99.3% | 98.6% | +0.6% |
| Erdafitinib | 99.0% | 99.1% | -0.0% |
| Futibatinib | 99.0% | 99.0% | -0.0% |
| Pemigatinib | 98.5% | 99.4% | -0.9% |
| Alpelisib | 97.8% | 98.6% | -0.8% |
| Ponatinib | 97.4% | 96.7% | +0.7% |
| Deucravacitinib | 94.5% | 93.3% | +1.2% |
| Tenalisib | 93.8% | 98.0% | -4.2% |
| Pralsetinib | 93.5% | 90.6% | +2.9% |
| Axitinib | 93.0% | 93.1% | -0.1% |
| Brigatinib | 90.3% | 74.6% | +15.6% |
| Nintedanib | 89.5% | 91.0% | -1.4% |
| Lenvatinib | 87.1% | 79.9% | +7.2% |
| Selpercatinib | 81.7% | 86.6% | -5.0% |
| Pazopanib | 80.8% | 78.7% | +2.1% |
| Pacritinib | 73.8% | 70.5% | +3.3% |
| Entrectinib | 72.7% | 73.3% | -0.7% |
| Ibrutinib | 72.0% | — | — |
| Tepotinib | 69.1% | — | — |
| Sunitinib | 68.5% | 66.2% | +2.3% |
| Defactinib | 67.8% | 65.7% | +2.1% |
| Fedratinib | 63.9% | 67.1% | -3.2% |
| Ripretinib | 60.9% | — | — |
| Repotrectinib | 51.9% | — | — |
| Tivozanib | 45.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_upper_aerodigestive_tract | Brain/CNS | ref |
| carcinoma_stomach | Stomach/Digestive Tract | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.2ms